Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

por Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Publicado 2011

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

por Figueiredo, J.C., Ihenacho, U., Merin, N.M., Hamid, O., Darrah, J., Gong, J., Paquette, R., Mita, A.C., Vescio, R., Mehmi, I., Basho, R., Salvy, S.J., Shirazipour, C.H., Caceres, N., Finster, L.J., Coleman, B., Arnow, H.U., Florindez, L., Sobhani, K., Prostko, J.C., Frias, E.C., Stewart, J.L., Merchant, A., Reckamp, K.L.
Publicado 2022